Genovate Biotechnology Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Genovate Biotechnology has a total shareholder equity of NT$1.5B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$1.6B and NT$145.5M respectively. Genovate Biotechnology's EBIT is NT$27.0M making its interest coverage ratio -4.8. It has cash and short-term investments of NT$538.6M.
Anahtar bilgiler
0%
Borç/özkaynak oranı
NT$0
Borç
| Faiz karşılama oranı | -4.8x |
| Nakit | NT$538.60m |
| Eşitlik | NT$1.50b |
| Toplam yükümlülükler | NT$145.53m |
| Toplam varlıklar | NT$1.65b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Reflecting on Genovate Biotechnology's (GTSM:4130) Share Price Returns Over The Last Five Years
Mar 09
Does It Make Sense To Buy Genovate Biotechnology Co., Ltd. (GTSM:4130) For Its Yield?
Feb 10Genovate Biotechnology Co., Ltd.'s (GTSM:4130) Dismal Stock Performance Reflects Weak Fundamentals
Jan 04
How Much Did Genovate Biotechnology's(GTSM:4130) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 08Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 4130's short term assets (NT$777.1M) exceed its short term liabilities (NT$137.1M).
Uzun Vadeli Yükümlülükler: 4130's short term assets (NT$777.1M) exceed its long term liabilities (NT$8.4M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 4130 is debt free.
Borcun Azaltılması: 4130 had no debt 5 years ago.
Borç Kapsamı: 4130 has no debt, therefore it does not need to be covered by operating cash flow.
Faiz Kapsamı: 4130 has no debt, therefore coverage of interest payments is not a concern.